These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29185433)

  • 1. Focus on RNA interference: from nanoformulations to in vivo delivery.
    Karp JM; Peer D
    Nanotechnology; 2018 Jan; 29(1):010201. PubMed ID: 29185433
    [No Abstract]   [Full Text] [Related]  

  • 2. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
    Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
    Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.
    Kim B; Park JH; Sailor MJ
    Adv Mater; 2019 Dec; 31(49):e1903637. PubMed ID: 31566258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical issues in delivery of RNAi therapeutics in vivo.
    Rivera S; Yuan F
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1279-91. PubMed ID: 22201583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNAi therapeutics: an update on delivery.
    Nguyen T; Menocal EM; Harborth J; Fruehauf JH
    Curr Opin Mol Ther; 2008 Apr; 10(2):158-67. PubMed ID: 18386228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA interference: From tools to therapies.
    Baker M
    Nature; 2010 Apr; 464(7292):1225. PubMed ID: 20414309
    [No Abstract]   [Full Text] [Related]  

  • 7. RNA interference: Homing in on delivery.
    Baker M
    Nature; 2010 Apr; 464(7292):1225-8. PubMed ID: 20414308
    [No Abstract]   [Full Text] [Related]  

  • 8. Advances in Specific Gene Knockdown of Therapeutic Targets by RNA Interference.
    Praça FG; Lopes Badra Bentley MV
    Curr Pharm Des; 2018; 24(23):2631. PubMed ID: 30378492
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent advances in siRNA delivery.
    Sarisozen C; Salzano G; Torchilin VP
    Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNAi therapeutics: SNALPing siRNAs in vivo.
    Rossi JJ
    Gene Ther; 2006 Apr; 13(7):583-4. PubMed ID: 17526070
    [No Abstract]   [Full Text] [Related]  

  • 11. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy.
    Lee SY; Yang CY; Peng CL; Wei MF; Chen KC; Yao CJ; Shieh MJ
    Biomaterials; 2016 Apr; 86():92-105. PubMed ID: 26896610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs.
    Akinc A; Maier MA; Manoharan M; Fitzgerald K; Jayaraman M; Barros S; Ansell S; Du X; Hope MJ; Madden TD; Mui BL; Semple SC; Tam YK; Ciufolini M; Witzigmann D; Kulkarni JA; van der Meel R; Cullis PR
    Nat Nanotechnol; 2019 Dec; 14(12):1084-1087. PubMed ID: 31802031
    [No Abstract]   [Full Text] [Related]  

  • 13. The current state and future directions of RNAi-based therapeutics.
    Setten RL; Rossi JJ; Han SP
    Nat Rev Drug Discov; 2019 Jun; 18(6):421-446. PubMed ID: 30846871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SiRNA delivery: challenges and role of carrier systems.
    Shegokar R; Al Shaal L; Mishra PR
    Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-Based Nanocarriers for RNA Delivery.
    Xue HY; Guo P; Wen WC; Wong HL
    Curr Pharm Des; 2015; 21(22):3140-7. PubMed ID: 26027572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNAi therapeutics: the teenage years.
    Perkel JM
    Biotechniques; 2012 Jun; 52(6):355-7. PubMed ID: 22668413
    [No Abstract]   [Full Text] [Related]  

  • 17. Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics.
    Akhtar S
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1347-62. PubMed ID: 20929276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status of non-viral vectors for siRNA delivery].
    Yang FF; Huang W; Li YF; Gao ZG
    Yao Xue Xue Bao; 2011 Dec; 46(12):1436-43. PubMed ID: 22375415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.
    Ward DM; Shodeinde AB; Peppas NA
    Adv Healthc Mater; 2021 Jul; 10(13):e2100350. PubMed ID: 33973393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide-Aptamer Coassembly Nanocarrier for Cancer Therapy.
    Ma Y; Li W; Zhou Z; Qin X; Wang D; Gao Y; Yu Z; Yin F; Li Z
    Bioconjug Chem; 2019 Mar; 30(3):536-540. PubMed ID: 30702869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.